Lenigron (Timolol Maleate, Bimatoprost)

Lenigron, a combination beta‑adrenergic antagonist and prostaglandin analog, is used to manage conditions that involve elevated intra‑ocular pressure.

• Open-angle glaucoma: reduces intra‑ocular pressure to slow visual field loss.
• Ocular hypertension: lowers intra‑ocular pressure to prevent progression to glaucoma.
• Pseudoexfoliative glaucoma: assists in pressure control where exfoliative material increases outflow resistance.
• Secondary open-angle glaucoma: provides additional pressure reduction when monotherapy is insufficient.

• Timolol maleate blocks β1 and β2 adrenergic receptors in the ciliary body, decreasing aqueous humor production. Bimatoprost activates prostaglandin F2α receptors in the uveoscleral pathway, enhancing outflow of aqueous humor. This combined effect is maintained with once‑daily dosing, providing consistent pressure control throughout the day.

Lenigron may cause ocular and systemic adverse reactions; they are categorized by frequency.

Common Side Effects

• Eye irritation: mild burning or stinging upon instillation.
• Blurred vision: transient visual disturbance after dosing.
• Conjunctival hyperemia: redness of the eye.
• Itching: localized pruritus around the eye.
• Dry eye: decreased tear production leading to discomfort.
• Headache: mild headache reported by some patients.

Serious or Rare Side Effects

• Severe allergic reaction: swelling, rash, or difficulty breathing.
• Uveitis: inflammation of the uveal tract requiring medical attention.
• Macular edema: fluid accumulation in the macula affecting vision.
• Decreased visual acuity: sudden loss of sharpness.
• Systemic beta‑blocker effects: bradycardia, hypotension, or bronchospasm.

Before prescribing Lenigron, clinicians should evaluate patient history and monitor for specific risks.

• Pregnancy: safety not established; use only if benefits outweigh risks.
• Breastfeeding: caution as drug may be excreted in milk.
• Respiratory disease: avoid in patients with severe asthma or COPD due to beta‑blockade.
• Cardiac disease: monitor for bradycardia or heart block in patients with conduction disorders.
• Systemic beta‑blocker therapy: assess for additive hypotensive or cardiac effects.
• Store at ambient temperature: keep below 25 °C, protect from light and moisture in original container.

Lenigron can interact with other medications; some combinations require avoidance while others need close monitoring.

Major Interactions (Avoid)

• Systemic non‑selective beta‑blockers: may cause excessive bradycardia or hypotension.
• Other prostaglandin analog eye drops: increase risk of ocular inflammation.
• Monoamine oxidase inhibitors (MAOIs): potential for severe bronchospasm when combined with timolol.

Moderate Interactions (Monitor Closely)

• Anticholinergic eye drops: may reduce intra‑ocular pressure‑lowering efficacy.
• Topical corticosteroids: can counteract pressure‑lowering effect and raise IOP.
• Sympathomimetic agents (e.g., epinephrine): may diminish timolol’s effect on aqueous production.